Synaptogenix (NASDAQ:TAOX) Stock Rating Lowered by Wall Street Zen

Synaptogenix (NASDAQ:TAOX) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Sunday, Wall Street Zen reports.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Synaptogenix in a report on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Synaptogenix currently has an average rating of “Sell”.

Synaptogenix Stock Performance

Synaptogenix stock opened at $4.43 on Friday. The firm has a market cap of $33.14 million, a PE ratio of -1.15 and a beta of 1.73. The firm’s 50 day moving average price is $3.88 and its two-hundred day moving average price is $4.33. Synaptogenix has a twelve month low of $3.07 and a twelve month high of $10.00.

Synaptogenix (NASDAQ:TAOX) last released its earnings results on Thursday, August 13th. The company reported ($1.83) earnings per share (EPS) for the quarter. Synaptogenix had a negative return on equity of 128.51% and a negative net margin of 2,153.97%.The company had revenue of $0.09 million during the quarter.

About Synaptogenix

Synaptogenix, Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative and cognitive disorders. The company’s research has centered on synaptic function and the potential to improve memory and cognition.

Synaptogenix’s primary development program has involved bryostatin-1, an investigational drug studied for the treatment of Alzheimer’s disease and other conditions involving cognitive impairment. The company has also explored potential applications in related neurological disorders, although its product candidates are investigational and have not been approved for commercial use.

The company was formerly known as Neurotrope, Inc and adopted the Synaptogenix name as part of a corporate rebranding.